BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS). METHODS: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment. RESULTS: From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001). CONCLUSIONS: FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer / Bertolini, Federica; Malavasi, Norma; Scarabelli, Laura; Fiocchi, Federica; Bagni, Bruno; DEL GIOVANE, Cinzia; Colucci, G; Gerunda, Giorgio Enrico; Depenni, Roberta; Zironi, S; Fontana, A; Pettorelli, Elisa; Luppi, G; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 1532-1827. - STAMPA. - 104:(2011), pp. 1079-1084. [10.1038/bjc.2011.43. Epub 2011 Mar 8.]

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.

BERTOLINI, Federica;MALAVASI, Norma;SCARABELLI, Laura;FIOCCHI, Federica;BAGNI, Bruno;DEL GIOVANE, Cinzia;GERUNDA, Giorgio Enrico;DEPENNI, Roberta;PETTORELLI, Elisa;CONTE, Pierfranco
2011

Abstract

BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS). METHODS: In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment. RESULTS: From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001). CONCLUSIONS: FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
104
1079
1084
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer / Bertolini, Federica; Malavasi, Norma; Scarabelli, Laura; Fiocchi, Federica; Bagni, Bruno; DEL GIOVANE, Cinzia; Colucci, G; Gerunda, Giorgio Enrico; Depenni, Roberta; Zironi, S; Fontana, A; Pettorelli, Elisa; Luppi, G; Conte, Pierfranco. - In: BRITISH JOURNAL OF CANCER. - ISSN 1532-1827. - STAMPA. - 104:(2011), pp. 1079-1084. [10.1038/bjc.2011.43. Epub 2011 Mar 8.]
Bertolini, Federica; Malavasi, Norma; Scarabelli, Laura; Fiocchi, Federica; Bagni, Bruno; DEL GIOVANE, Cinzia; Colucci, G; Gerunda, Giorgio Enrico; Depenni, Roberta; Zironi, S; Fontana, A; Pettorelli, Elisa; Luppi, G; Conte, Pierfranco
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1064618
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
social impact